Advertisement Article continues below this ad "We think this is state-of-the-art right now," he said
While individual results will vary, in clinical trials participants taking Semaglutide lost an average of 15-20 pounds, lost waist circumference, decreased their blood pressure, decreased BMI, lowered their A1C, lowered their fasting glucose, insulin, and cholesterol levels, experienced body composition changes (specifically visceral fat) over the course of 68 weeks
Le Collge canadien des endocrinologues (2023) recommande le smaglutide comme option majeure chez le patient diabtique avec un excs pondral, en particulier si le contrle glycmique nest pas atteint par les traitements conventionnels
Cardiac glucoside Digoxin has also been found to effectively inhibit translation of both HIF1 and HIF2 (160)